top of page
Laxxon has both an external pipeline and an in-house Advanced Patented Generic pipeline.
All products created with our SPID®-Technology manufacturing approach are patent protected, whether engineered in-house or with an external partner.
Product
2021
2022
2023
2024
2025
LXM.1
Epilepsy
LXM.3
Pain Relief
LXM.2
Diabetes
LXM.5
Parkinson's
LXM.11
Anticoagulant
LXM.16
ADHD
LXM.16
ADHD
External Programs
In-house Programs
Product Registration
Product Launch
Analytical Testing
Clinical Testing
Initial Test Printing
![Laxxon - [screen printing (white)].png](https://static.wixstatic.com/media/7a2e6b_7f598b48393c4b0e830f42edb0fb615d~mv2.png/v1/fill/w_100,h_62,al_c,q_85,usm_0.66_1.00_0.01,enc_auto/7a2e6b_7f598b48393c4b0e830f42edb0fb615d~mv2.png)
Product Pipeline
Laxxon has both an external pipeline and an in-house Advanced Patented Generic pipeline.
All products created with our SPID®-Technology manufacturing approach are patent protected, whether engineered in-house or with an external partner.
External Programs
In-house Programs
Initial Test Printing
Analytical Testing
Clinical Testing
Product Registration
Product Launch
bottom of page